Non-formulary rivaroxaban (XARELTO) will be covered on the prescription drug benefit when **ALL** of the following criteria are met:

**Prevention of thrombosis (blood clot) in patients with non-valvular atrial fibrillation (a heart rhythm disorder)**

*(Rivaroxaban 15 mg and 20 mg)*

1. Documented diagnosis of atrial fibrillation on Problem List

AND

2. **CHA2DS2-VASc** score ≥ 2 or CHADS2 score ≥ 1 (these scores predict the risk of stroke in patients with atrial fibrillation)

AND

3. At least one of the following criteria documented in the medical record:
   - Undergoing cardioversion (a medical procedure that converts an irregular heart rhythm to a normal one using electricity or drugs)
   - Intolerance or contraindication to warfarin
   - History of intracranial hemorrhage (bleeding in the brain) on warfarin
   - Challenges in getting timely blood draws due to difficulty getting to the lab or getting blood draws
   - Failed to maintain therapeutic INR (blood clotting time) level (blood clotting time) or time in therapeutic range (TTR) less than 50% despite history of good adherence to warfarin dosing (patient’s TTR may be obtained from Kaiser’s Anticoagulation Management Program)

AND

4. Intolerance or contraindication to dabigatran or have a condition where dabigatran is not preferred, such as history of gastrointestinal (GI) bleed

**Treatment of ACUTE venous thromboembolism (VTE)**

*(Rivaroxaban 15 mg and 20 mg)*

1. Documented diagnosis of venous thromboembolism (DVT: deep vein thrombosis or PE: pulmonary embolism) on Problem List

AND

2. At least one of the following criteria documented in the medical record:
   - Intolerance or contraindication to warfarin
   - History of intracranial hemorrhage (bleeding in the brain) on warfarin
   - Compliance with INR (blood clotting time) monitoring is challenging due to lab inaccessibility or getting blood draws
   - Failed to maintain therapeutic INR (blood clotting time) level or time in therapeutic range less than 50% despite history of good adherence to warfarin dosing (patient’s TTR may be obtained from Kaiser’s Anticoagulation Management Program)

**Prevention of recurrent venous thromboembolism (VTE: a blood clot in the vein)**

*(Rivaroxaban 10 mg, 15 mg and 20 mg)*

1. Documented diagnosis of venous thromboembolism (DVT: deep vein thrombosis or PE: pulmonary embolism) on Problem List
AND
2. Intolerance or contraindication to dabigatran

AND
3. At least one of the following criteria documented in the medical record:
   - Intolerance or contraindication to warfarin
   - History of intracranial hemorrhage (bleeding in the brain) on warfarin
   - Challenges in getting timely blood draws due to difficulty getting to the lab or getting blood draws
   - Failed to maintain therapeutic INR (blood clotting time) level or time in therapeutic range (TTR) less than 50% despite history of good adherence to warfarin dosing (patient’s TTR may be obtained from Kaiser’s Anticoagulation Management Program)

Prophylaxis (prevention) of venous thromboembolism (VTE: a blood clot in the vein) post-hip or knee replacement surgery

(Rivaroxaban 10 mg)
1. Deep vein thrombosis (DVT) prevention in patients undergoing knee arthroplasty (up to 12 days) or hip arthroplasty (up to 35 days)